Mucosal nirsevimab levels in respiratory syncytial virus breakthrough bronchiolitis
A multivariate analysis (appendix pp 1–2) including potential influencing factors (time since nirsevimab injection, age at injection, history of bronchiolitis, ratio of nirsevimab/IgG, breastfeeding, and gestational age at birth) identified only the mucosal ratio of nirsevimab/IgG as statistically s...
Gespeichert in:
| Veröffentlicht in: | The Lancet infectious diseases 2024-11, Vol.24 (11), p.1192-1194 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1194 |
|---|---|
| container_issue | 11 |
| container_start_page | 1192 |
| container_title | The Lancet infectious diseases |
| container_volume | 24 |
| creator | Pillet, Sylvie Cantais, Aymeric Noailly, Blandine Jospin, Fabienne Zekre, Franck Boussetta-Charfi, Oulfa Chenafi-Adham, Sara Bourlet, Thomas Fourati, Slim Paul, Stéphane |
| description | A multivariate analysis (appendix pp 1–2) including potential influencing factors (time since nirsevimab injection, age at injection, history of bronchiolitis, ratio of nirsevimab/IgG, breastfeeding, and gestational age at birth) identified only the mucosal ratio of nirsevimab/IgG as statistically significantly associated with RSV infection (coefficient –1·38 [95% CI –2·663 to –0·101], p=0·034). Nirsevimab is administered intramuscularly and distributed through body fluids to the lower respiratory tract, where it blocks RSV entry through direct viral neutralisation.4,5 Mucosal RSV-specific IgA is associated with protection in the upper respiratory tract in animal models,7 low RSV-specific nasal IgA is a risk factor of RSV infection in adults with IgA memory deficiency,8 and IgA mediates recovery during primary RSV infection in young children ( |
| doi_str_mv | 10.1016/S1473-3099(24)00600-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_04871251v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1473309924006005</els_id><sourcerecordid>3115968802</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2203-13b3142b3b654aba42e2e7ac97859b06a33677216a1dd00b8dd1cacfadc421903</originalsourceid><addsrcrecordid>eNqFkU1v1DAQQC0EoqXwE0CRuLSHwIw_kviEqgoo0iIOhbNlO7OsSzZe7GSl_fd4N6UHLpzGM3ozHvsx9hrhHQI27-9QtqIWoPUll1cADUCtnrDzUpa1lKp9ejovyBl7kfM9ALYI8jk7E1poJbk4Z3dfZx-zHaoxpEz7sLWuGmhPQ67CWCXKu5DsFNOhyofRH6ZQ0H1Ic65cIvtr2qQ4_9yUJI5-E-IQppBfsmdrO2R69RAv2I9PH7_f3Narb5-_3Fyvas85iBqFEyi5E65R0jorOXFqrddtp7SDxgrRtC3HxmLfA7iu79Fbv7a9lxw1iAt2tczd2MHsUtk9HUy0wdxer8yxBrJrkSvcY2EvF3aX4u-Z8mS2IXsaBjtSnLMRiEo3XQe8oG__Qe_jnMbykiOlNSKKplBqoXyKOSdaP26AYI6GzMmQOX6_4dKcDBlV-t48TJ_dlvrHrr9KCvBhAYqDIoSSyT7Q6KkPifxk-hj-c8Uf12OfkQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3119911136</pqid></control><display><type>article</type><title>Mucosal nirsevimab levels in respiratory syncytial virus breakthrough bronchiolitis</title><source>Elsevier ScienceDirect Journals</source><creator>Pillet, Sylvie ; Cantais, Aymeric ; Noailly, Blandine ; Jospin, Fabienne ; Zekre, Franck ; Boussetta-Charfi, Oulfa ; Chenafi-Adham, Sara ; Bourlet, Thomas ; Fourati, Slim ; Paul, Stéphane</creator><creatorcontrib>Pillet, Sylvie ; Cantais, Aymeric ; Noailly, Blandine ; Jospin, Fabienne ; Zekre, Franck ; Boussetta-Charfi, Oulfa ; Chenafi-Adham, Sara ; Bourlet, Thomas ; Fourati, Slim ; Paul, Stéphane</creatorcontrib><description>A multivariate analysis (appendix pp 1–2) including potential influencing factors (time since nirsevimab injection, age at injection, history of bronchiolitis, ratio of nirsevimab/IgG, breastfeeding, and gestational age at birth) identified only the mucosal ratio of nirsevimab/IgG as statistically significantly associated with RSV infection (coefficient –1·38 [95% CI –2·663 to –0·101], p=0·034). Nirsevimab is administered intramuscularly and distributed through body fluids to the lower respiratory tract, where it blocks RSV entry through direct viral neutralisation.4,5 Mucosal RSV-specific IgA is associated with protection in the upper respiratory tract in animal models,7 low RSV-specific nasal IgA is a risk factor of RSV infection in adults with IgA memory deficiency,8 and IgA mediates recovery during primary RSV infection in young children (<8 months old).9 Although nirsevimab is an IgG, the mechanisms of mucosal protection are likely to be similar. [...]this study highlights the crucial role of sufficient mucosal nirsevimab in protecting infants against RSV bronchiolitis.</description><identifier>ISSN: 1473-3099</identifier><identifier>ISSN: 1474-4457</identifier><identifier>EISSN: 1474-4457</identifier><identifier>DOI: 10.1016/S1473-3099(24)00600-5</identifier><identifier>PMID: 39395423</identifier><language>eng</language><publisher>United States: Elsevier Ltd</publisher><subject>Age ; Animal models ; Body fluids ; Breast feeding ; Bronchopneumonia ; Gestational age ; Human health and pathology ; Immunoglobulin A ; Immunoglobulin G ; Immunological memory ; Immunology ; Infections ; Infectious diseases ; Injection ; Life Sciences ; Microbiology and Parasitology ; Monoclonal antibodies ; Mucosa ; Multivariate analysis ; Mutation ; Pediatrics ; Pulmonology and respiratory tract ; Respiratory syncytial virus ; Respiratory tract ; Risk factors ; Vaccinology ; Virology</subject><ispartof>The Lancet infectious diseases, 2024-11, Vol.24 (11), p.1192-1194</ispartof><rights>2024 Elsevier Ltd</rights><rights>2024. Elsevier Ltd</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2203-13b3142b3b654aba42e2e7ac97859b06a33677216a1dd00b8dd1cacfadc421903</cites><orcidid>0000-0002-8830-4273</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1473309924006005$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39395423$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-04871251$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Pillet, Sylvie</creatorcontrib><creatorcontrib>Cantais, Aymeric</creatorcontrib><creatorcontrib>Noailly, Blandine</creatorcontrib><creatorcontrib>Jospin, Fabienne</creatorcontrib><creatorcontrib>Zekre, Franck</creatorcontrib><creatorcontrib>Boussetta-Charfi, Oulfa</creatorcontrib><creatorcontrib>Chenafi-Adham, Sara</creatorcontrib><creatorcontrib>Bourlet, Thomas</creatorcontrib><creatorcontrib>Fourati, Slim</creatorcontrib><creatorcontrib>Paul, Stéphane</creatorcontrib><title>Mucosal nirsevimab levels in respiratory syncytial virus breakthrough bronchiolitis</title><title>The Lancet infectious diseases</title><addtitle>Lancet Infect Dis</addtitle><description>A multivariate analysis (appendix pp 1–2) including potential influencing factors (time since nirsevimab injection, age at injection, history of bronchiolitis, ratio of nirsevimab/IgG, breastfeeding, and gestational age at birth) identified only the mucosal ratio of nirsevimab/IgG as statistically significantly associated with RSV infection (coefficient –1·38 [95% CI –2·663 to –0·101], p=0·034). Nirsevimab is administered intramuscularly and distributed through body fluids to the lower respiratory tract, where it blocks RSV entry through direct viral neutralisation.4,5 Mucosal RSV-specific IgA is associated with protection in the upper respiratory tract in animal models,7 low RSV-specific nasal IgA is a risk factor of RSV infection in adults with IgA memory deficiency,8 and IgA mediates recovery during primary RSV infection in young children (<8 months old).9 Although nirsevimab is an IgG, the mechanisms of mucosal protection are likely to be similar. [...]this study highlights the crucial role of sufficient mucosal nirsevimab in protecting infants against RSV bronchiolitis.</description><subject>Age</subject><subject>Animal models</subject><subject>Body fluids</subject><subject>Breast feeding</subject><subject>Bronchopneumonia</subject><subject>Gestational age</subject><subject>Human health and pathology</subject><subject>Immunoglobulin A</subject><subject>Immunoglobulin G</subject><subject>Immunological memory</subject><subject>Immunology</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Injection</subject><subject>Life Sciences</subject><subject>Microbiology and Parasitology</subject><subject>Monoclonal antibodies</subject><subject>Mucosa</subject><subject>Multivariate analysis</subject><subject>Mutation</subject><subject>Pediatrics</subject><subject>Pulmonology and respiratory tract</subject><subject>Respiratory syncytial virus</subject><subject>Respiratory tract</subject><subject>Risk factors</subject><subject>Vaccinology</subject><subject>Virology</subject><issn>1473-3099</issn><issn>1474-4457</issn><issn>1474-4457</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNqFkU1v1DAQQC0EoqXwE0CRuLSHwIw_kviEqgoo0iIOhbNlO7OsSzZe7GSl_fd4N6UHLpzGM3ozHvsx9hrhHQI27-9QtqIWoPUll1cADUCtnrDzUpa1lKp9ejovyBl7kfM9ALYI8jk7E1poJbk4Z3dfZx-zHaoxpEz7sLWuGmhPQ67CWCXKu5DsFNOhyofRH6ZQ0H1Ic65cIvtr2qQ4_9yUJI5-E-IQppBfsmdrO2R69RAv2I9PH7_f3Narb5-_3Fyvas85iBqFEyi5E65R0jorOXFqrddtp7SDxgrRtC3HxmLfA7iu79Fbv7a9lxw1iAt2tczd2MHsUtk9HUy0wdxer8yxBrJrkSvcY2EvF3aX4u-Z8mS2IXsaBjtSnLMRiEo3XQe8oG__Qe_jnMbykiOlNSKKplBqoXyKOSdaP26AYI6GzMmQOX6_4dKcDBlV-t48TJ_dlvrHrr9KCvBhAYqDIoSSyT7Q6KkPifxk-hj-c8Uf12OfkQ</recordid><startdate>20241101</startdate><enddate>20241101</enddate><creator>Pillet, Sylvie</creator><creator>Cantais, Aymeric</creator><creator>Noailly, Blandine</creator><creator>Jospin, Fabienne</creator><creator>Zekre, Franck</creator><creator>Boussetta-Charfi, Oulfa</creator><creator>Chenafi-Adham, Sara</creator><creator>Bourlet, Thomas</creator><creator>Fourati, Slim</creator><creator>Paul, Stéphane</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><general>New York, NY : Elsevier Science ; The Lancet Pub. Group, 2001</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><orcidid>https://orcid.org/0000-0002-8830-4273</orcidid></search><sort><creationdate>20241101</creationdate><title>Mucosal nirsevimab levels in respiratory syncytial virus breakthrough bronchiolitis</title><author>Pillet, Sylvie ; Cantais, Aymeric ; Noailly, Blandine ; Jospin, Fabienne ; Zekre, Franck ; Boussetta-Charfi, Oulfa ; Chenafi-Adham, Sara ; Bourlet, Thomas ; Fourati, Slim ; Paul, Stéphane</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2203-13b3142b3b654aba42e2e7ac97859b06a33677216a1dd00b8dd1cacfadc421903</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Age</topic><topic>Animal models</topic><topic>Body fluids</topic><topic>Breast feeding</topic><topic>Bronchopneumonia</topic><topic>Gestational age</topic><topic>Human health and pathology</topic><topic>Immunoglobulin A</topic><topic>Immunoglobulin G</topic><topic>Immunological memory</topic><topic>Immunology</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Injection</topic><topic>Life Sciences</topic><topic>Microbiology and Parasitology</topic><topic>Monoclonal antibodies</topic><topic>Mucosa</topic><topic>Multivariate analysis</topic><topic>Mutation</topic><topic>Pediatrics</topic><topic>Pulmonology and respiratory tract</topic><topic>Respiratory syncytial virus</topic><topic>Respiratory tract</topic><topic>Risk factors</topic><topic>Vaccinology</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pillet, Sylvie</creatorcontrib><creatorcontrib>Cantais, Aymeric</creatorcontrib><creatorcontrib>Noailly, Blandine</creatorcontrib><creatorcontrib>Jospin, Fabienne</creatorcontrib><creatorcontrib>Zekre, Franck</creatorcontrib><creatorcontrib>Boussetta-Charfi, Oulfa</creatorcontrib><creatorcontrib>Chenafi-Adham, Sara</creatorcontrib><creatorcontrib>Bourlet, Thomas</creatorcontrib><creatorcontrib>Fourati, Slim</creatorcontrib><creatorcontrib>Paul, Stéphane</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>The Lancet infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pillet, Sylvie</au><au>Cantais, Aymeric</au><au>Noailly, Blandine</au><au>Jospin, Fabienne</au><au>Zekre, Franck</au><au>Boussetta-Charfi, Oulfa</au><au>Chenafi-Adham, Sara</au><au>Bourlet, Thomas</au><au>Fourati, Slim</au><au>Paul, Stéphane</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mucosal nirsevimab levels in respiratory syncytial virus breakthrough bronchiolitis</atitle><jtitle>The Lancet infectious diseases</jtitle><addtitle>Lancet Infect Dis</addtitle><date>2024-11-01</date><risdate>2024</risdate><volume>24</volume><issue>11</issue><spage>1192</spage><epage>1194</epage><pages>1192-1194</pages><issn>1473-3099</issn><issn>1474-4457</issn><eissn>1474-4457</eissn><abstract>A multivariate analysis (appendix pp 1–2) including potential influencing factors (time since nirsevimab injection, age at injection, history of bronchiolitis, ratio of nirsevimab/IgG, breastfeeding, and gestational age at birth) identified only the mucosal ratio of nirsevimab/IgG as statistically significantly associated with RSV infection (coefficient –1·38 [95% CI –2·663 to –0·101], p=0·034). Nirsevimab is administered intramuscularly and distributed through body fluids to the lower respiratory tract, where it blocks RSV entry through direct viral neutralisation.4,5 Mucosal RSV-specific IgA is associated with protection in the upper respiratory tract in animal models,7 low RSV-specific nasal IgA is a risk factor of RSV infection in adults with IgA memory deficiency,8 and IgA mediates recovery during primary RSV infection in young children (<8 months old).9 Although nirsevimab is an IgG, the mechanisms of mucosal protection are likely to be similar. [...]this study highlights the crucial role of sufficient mucosal nirsevimab in protecting infants against RSV bronchiolitis.</abstract><cop>United States</cop><pub>Elsevier Ltd</pub><pmid>39395423</pmid><doi>10.1016/S1473-3099(24)00600-5</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0002-8830-4273</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1473-3099 |
| ispartof | The Lancet infectious diseases, 2024-11, Vol.24 (11), p.1192-1194 |
| issn | 1473-3099 1474-4457 1474-4457 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_04871251v1 |
| source | Elsevier ScienceDirect Journals |
| subjects | Age Animal models Body fluids Breast feeding Bronchopneumonia Gestational age Human health and pathology Immunoglobulin A Immunoglobulin G Immunological memory Immunology Infections Infectious diseases Injection Life Sciences Microbiology and Parasitology Monoclonal antibodies Mucosa Multivariate analysis Mutation Pediatrics Pulmonology and respiratory tract Respiratory syncytial virus Respiratory tract Risk factors Vaccinology Virology |
| title | Mucosal nirsevimab levels in respiratory syncytial virus breakthrough bronchiolitis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T18%3A54%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mucosal%20nirsevimab%20levels%20in%20respiratory%20syncytial%20virus%20breakthrough%20bronchiolitis&rft.jtitle=The%20Lancet%20infectious%20diseases&rft.au=Pillet,%20Sylvie&rft.date=2024-11-01&rft.volume=24&rft.issue=11&rft.spage=1192&rft.epage=1194&rft.pages=1192-1194&rft.issn=1473-3099&rft.eissn=1474-4457&rft_id=info:doi/10.1016/S1473-3099(24)00600-5&rft_dat=%3Cproquest_hal_p%3E3115968802%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3119911136&rft_id=info:pmid/39395423&rft_els_id=S1473309924006005&rfr_iscdi=true |